Copd Exacerbation
Odds for mortality elevated in COPD exacerbation, COVID-19 hospitalization
BOSTON — Having a COPD exacerbation hospitalization in combination with COVID-19 vs. no COVID-19 significantly raised the odds for mortality and invasive ventilation, according to a poster presented at the CHEST Annual Meeting.
Metabolically healthy obesity heightens respiratory, cardiac complication odds in COPD
BOSTON — Older adults hospitalized for an acute COPD exacerbation with vs. without metabolically healthy obesity were more likely to experience respiratory and cardiac complications, according to data presented at the CHEST Annual Meeting.
AI capable of predicting COPD exacerbations with continuous temperature data
Using continuous temperature monitoring data from patients with COPD, an AI was able to predict exacerbations, according to a poster presented at the European Respiratory Society International Congress.
Early triple combination COPD therapy decreases exacerbations, cardiopulmonary events
Patients with COPD on budesonide/glycopyrrolate/formoterol fumarate within 30 days of an exacerbation had fewer future exacerbations and severe cardiopulmonary events, according to a study poster.
BODE index score does not change dupilumab efficacy in COPD with type 2 inflammation
Dupilumab’s impact on exacerbation rate and lung function in adults with COPD and type 2 inflammation did not differ based on BODE index score, according to a poster presented at the European Respiratory Society International Congress.
Speech features change during onset, peak of COPD exacerbation
Patients with COPD experience changes in voice pitch and jitter during the onset and peak of an exacerbation, according to a poster presented at the European Respiratory Society International Congress.
Pooled BOREAS, NOTUS analysis: Dupilumab beneficial in COPD with type 2 inflammation
Dupilumab led to improvement and was safe in adults with moderate to severe COPD and type 2 inflammation at week 52, according to a pooled analysis of BOREAS and NOTUS presented at the European Respiratory Society International Congress.
Lung function improvement in severe emphysema sustained over 5 years with Zephyr Valves
Patients with severe emphysema had lasting lung function improvement 5 years after bronchoscopic lung volume reduction with Zephyr Valves, according to a poster presented at the European Respiratory Society International Congress.
Exacerbation risk factors identified in patients with COPD, no recent exacerbations
Four variables, including chronic bronchitis and high symptom burden, heightened the rate of exacerbations among patients with COPD and no recent exacerbations, according to results published in Annals of the American Thoracic Society.
FDA grants breakthrough designation to tezepelumab for COPD
Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype, according to an Amgen press release.